CURRENT AND UPCOMING ANTICOAGULATION OPTIONS FOR DVT, PE AND ATRIAL FIBRILATION
TORONTO PARK HYATT HOTEL, TORONTO, ON, May 23rd 2008

Learning Objectives:

• Apply the updated treatment for DVT and PE
• Understand new developments in antithrombotic therapy for
  atrial fi brillation
• Discuss the rationale and process of new drug development
• Reflect upon recent data on the effi cacy of novel agents
• Thrombosis interest Group of Canada (TIGC) is dedicated to furthering
  education and research in the prevention and treatment of thrombosis.”

TIGC on ePresence (click on links below to view archived presentations) Current & Upcoming Anticoagulation Options for DVT, PE & Atrial Fibrilation - New Oral Anticoagulants: The Case of Rivaroxaban - Dr. M. Crowther Current & Upcoming Anticoagulation Options for DVT, PE & Atrial Fibrilation - Current Anticoagulation Recommendations for DVT & PE - Dr. A. Roussin Current & Upcoming Anticoagulation Options for DVT, PE & Atrial Fibrilation - Current Anticoagulation Recommendations for AF - Dr. M. Talajic Current & Upcoming Anticoagulation Options for DVT, PE & Atrial Fibrilation - Round Table - Drs. M. Crowther, A. Roussin & M. Talajic